Completed PHASE2 INTERVENTIONAL NCT00002907

Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma

PHASE II CLINICAL EVALUATION OF BRYOSTATIN 1 IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA

Sponsor: Barbara Ann Karmanos Cancer Institute

Conditions Multiple Myeloma and Plasma Cell Neoplasm

Updated 5 times since 2017 Last updated: Apr 3, 2013 Started: Jan 31, 1997 Primary completion: Jan 31, 1999 Completion: Nov 30, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Myeloma and Plasma Cell Neoplasm and is currently completed. Barbara Ann Karmanos Cancer Institute leads this study, which shows 5 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Data source: Barbara Ann Karmanos Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Detroit, United States